JUN 1 8 2003 H

\$216 DONT 62423

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number	09/481,572
Filing Date	January 11, 2000
First Named Inventor	SHAN et al
Group Art Unit	1654
Examiner Name	M. Meller
Attorney Docket Number	2968-160

Title of the Invention: HYPERICIN AND HYPERICIN EXTRACT: SPECIFIC T-TYPE CALCIUM CHANNEL BLOCKER

## **AMENDMENT**

**RECEIVED** 

Mail Stop Non-Fee Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

JUN 2 3 2003

**TECH CENTER 1600/2900** 

Dear Sir:

Applicants request entry of the amendments below and reconsideration of the application.

In the Claims:

Please add the following new claim to the application:

26. The method of claim 1, wherein the health disorder is chronic heart failure.

<u>Remarks</u>

In the event this paper is not considered to be timely filed, the applicants respectfully petition for an appropriate extension of time. Any fee for such an extension together with any additional fees that may be due with respect to this paper, may be charged to Counsel's Deposit Account No. 02-2135.

RESPECTFULLY SUBMITTED,				
NAME AND Robert B. Murray, Reg. No. 22,980 REG. NUMBER				
SIGNATURE		Kelden	DATE	June 18, 2003
ADDRESS Rothwell, Figg, Ernst & Manbeck, Suite 800, 1425 K Street, N.W. Washington D.C. 20005 Telephone 202/783-6040, Telefax 202/783-6031				



CPA/1654

## CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing.

APPLICABLE

CHECK BOX, IF

Only for Continuation or Divisional applications under 37 CFR 1.53(d)

[ ] DUPLICATE

Address to:

Assistant Commissioner for Patents Box CPA Washington, D.C. 20231 Attorney Docket No. of Prior Application

First Named Inventor

SHAN et al

Examiner Name

M. Meller

JUN 2 3 2003

Group Art Unit 1654

Express Mail Label No.

This is a request for a continuation application under 37 CFR 1.53(d) (continued prosecution application (CPA)) of prior application number 09/481,572 filed on January 11, 2000 entitled HYPERICIN AND HYPERICIN EXTRACT: SPECIFIC T-TYPE CALCIUM CHANNEL BLOCKER.

## **NOTES**

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b) or (2) the national stage of an international application in compliance with 35 U.S.C. 371. Effective May 29, 2000, a CPA may only be filed in a utility or a plant application if the prior nonprovisional application was filed before May 29, 2000. A CPA may be filed in a design application regardless of the filing date of the prior application.

**C-I-P NOT PERMITTED:** A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

**EXPRESS ABANDONMENT OF PRIOR APPLICATION:** The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

**35 U.S.C. 120 STATEMENT:** In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

1. 🔲	Enter the unentered amendment previously filed on under 37 CFR 1.116 in the prior nonprovisional application
2. X	A preliminary amendment is enclosed.
3. 🔲	This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).
	<b>DELETE</b> the following inventor(s) named in the prior nonprovisonal application:
b.	The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
	•

06/19/2003 CNGUYEN 00000044 09481572

	ormation Disclosure	Statement (	_	ent (PTO/SB/81) is enclo sed:	sed.	
CLAIMS	(1) FOR	(2) NUME	BER FILED	(3) NUMBER EXTRA	(4) RATE (Small Entity)	(5) CALCULATIONS
	TOTAL CLAIMS		<b>6</b> -20 =		X\$ 9.00 =	\$
	INDEPENDENT CLAIMS		1 - 3=		X \$ 42.00 =	
	MULTIPLE DEPE	TIPLE DEPENDENT CLAIM (if applicable)			+ \$140.00 =	
		BASIC FE				375.00
				<del></del>	TOTAL =	\$ 375.00
A check in the amount of \$ 375_ is enclosed.  Payment by credit card. Form PTO-2038 is enclosed.  Applicant requests suspension of action under 37 CFR 1.103(b) for a period of months (not to exceed 3 months) and the fee under 37 CFR 1.17(i) enclosed.  New Attorney Docket Number, if desired 2968-160  Receipt for Facsimile Transmitted CPA (PTO/SB/29A)  Return Receipt Postcard (Should be specifically itemized, See MPEP 503)  Request and certification under 35 USC 122(b)(2)(B)(i) for nonpublication.  Other: Three Month Extension of Time, Fee Transmittal Sheet  **NOTE:**  The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.						
	·	14.	NEW CORR	RESPONDENCE ADDRI	ESS	
X Cus	stomer Number or B	ar Code Lab	el <b>6449</b>			
Name	Robert B		<del></del>			-
Address	Rothwell, Figg, Ernst & Manbeck Suite 800, 1425 K Street, N.W.					
City	Washing	ton S	State	D.C.	Zip Code	20005
Country	U.S.A.	7	elephone	202-783-6040	Fax	202-783-6031

<del>3</del>00

15. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED		
NAME & REG. NUMBER	Robert B. Murray Reg. No. 22,980	
SIGNATURE	Call the	
DATE	June 18, 2003	